Loading...
XSWXSPEX
Market cap2mUSD
Jul 31, Last price  
0.05CHF
Name

Spexis AG

Chart & Performance

D1W1MN
XSWX:SPEX chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
-66.24%
Revenues
Net income
CFO
Earnings
May 29, 2025

Profile

Spexis AG, a clinical-stage biopharmaceutical company, engages in discovering, developing, in-licensing, and acquiring molecules for rare diseases and cancer. Its products pipeline includes ColiFin, an inhaled colistimethate sodium product that is in the phase 3 trial for the treatment of cystic fibrosis (CF) infections; Inhaled Murepavadin, a novel class inhaled antibiotic which is in the phase 1 development stage to treat Pseudomonas aeruginosa infection in people with CF; EBX-002 for non-tuberculous mycobacterial lung infections; Balixafortide for oncology and non-oncology indications; New CXCR4 for treating orphan and hematological malignancies, and non-oncology indications; and Outer Membrane Protein Targeting Antibiotic BamA and lipopolysaccharide transport protein A programs. Spexis AG is headquartered in Allschwil, Switzerland.
IPO date
May 15, 2018
Employees
Domiciled in
CH
Incorporated in
CH

Valuation

No data to show